PolyPid Ltd. provided a corporate update on February 12, 2025, in conjunction with its fourth quarter and full-year 2024 financial results. The company reiterated the positive recommendation by the DSMB to continue enrollment of the Phase 3 SHIELD II trial of D-PLEX100 to 800 patients.
The SHIELD II trial has enrolled more than 700 patients to date, with enrollment completion expected in March 2025. Top-line results from the trial are anticipated in the second quarter of 2025.
PolyPid also confirmed the completion of its private placement of up to $41 million, with proceeds and the exercise of data-triggered warrants expected to extend the company's cash runway beyond potential NDA approval. The company welcomed Mr. Yitzchak Jacobovitz to its Board of Directors, noting his extensive healthcare investment experience.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.